Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of OC-001 in locally advanced or metastatic cancers has been terminated according to its clinical trials registry listing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Gastric Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• OC-001 (OC-001)

Snippet

Sponsor: Ocellaris Pharma, Inc. | Conditions: Cancer, Neoplasms | Phase 1, Phase 2 | Status: TERMINATED